Abstract: Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study us cr ip t Nguyen3, James M. Musser2,3, Howard J. Huang4, Michael G. Liebl1,* 1 Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA 2 Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist M 3 an USA Research Institute, Houston, Texas, USA ce Houston, TX, USA d Division of Pulmonology, Pulmonary, Critical Care & Sleep Medicine, Houston Methodist Hospital, pt e 4 Ac *Corresponding author: Michael G. Liebl, PharmD, BCPS; 7550 Greenbriar Dr. RB6-126, Houston, TX, USA 77030; Ph: 346.356.1757; Email: mliebl@houstonmethodist.org Alternate corresponding author: © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Megan H. Cooper1, Paul A. Christensen2, Eric Salazar2, Katherine K. Perez1,2, Edward A. Graviss3, Duc Megan H. Cooper, PharmD; 6565 Fannin St, DB1-09, Houston, TX, USA 77030; Ph: 713-441-7055; Email: mcooper@houstonmethodist.org Summary: We assessed the outcomes of 2,879 SARS-CoV-2-positive patients transfused with one of t cohort. We found that administration of mAbs significantly reduced 28-day hospitalizations and us cr ip mortality. Abstract Background: SARS-CoV-2 continues to spread globally and cause significant morbidity and mortality. an Anti-spike protein monoclonal antibody (mAb) therapy has been shown to prevent progression to severe COVID-19 disease. The objective of this study was to report the outcomes of high-risk, SARS- M CoV-2-positive patients infused with one of the three mAb available through FDA emergency use d authorization (EUA). pt e Methods: A total of 4,328 SARS-CoV-2-positive patients that satisfied EUA criteria for eligibility for receiving mAb therapy were infused with bamlanivimab or combination therapies bamlanivimab- ce etesevimab or casirivimab-imdevimab from November 22, 2020, to May 31, 2021, at six infusion clinics and multiple emergency departments within the eight Houston Methodist Hospitals in Ac Houston, Texas. The primary outcome of hospital admission within 14- and 28-days post-infusion was assessed relative to a propensity-score matched cohort, matched based on age, race/ethnicity, median income by zip code, body mass index, comorbidities, and positive PCR date. Secondary outcomes included ICU admission and mortality. Results: A total of 2,879 infused patients and matched controls were included in the analysis, including 1,718 patients infused with bamlanivimab, 346 patients infused with bamlanivimab- 2 three available monoclonal antibody..